Back to Rare Disease
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT03384420

NCT03384420
Completed Phase 2

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with Pearson Syndrome, confirmed by a genetic test showing a problem in your mitochondrial DNA (the DNA found in the energy-producing parts of your cells).
  • Your mother's mitochondrial DNA has been tested and shown to be normal.
  • You are between 3 years old and just before your 18th birthday.
  • You do not need regular blood transfusions to stay healthy.
  • You have at least one of the following health issues: unusually high levels of lactic acid in your blood; episodes of serious metabolic (body chemistry) crises in the past year; kidney problems that do not require dialysis, or signs that the kidneys are not filtering properly; or poor growth or difficulty gaining weight as expected.

Who may not be able to join:

  • No mitochondrial mutation or deletion can be found through testing.
  • You or your mother has tested positive for a certain microbiological infection (confirm with trial site for exact details).
  • You are not able to undergo a procedure called leukapheresis, which is a process that collects white blood cells from your blood.
  • You have a serious long-term infection, cancer, or another condition that could put you at risk or make the study results harder to understand.
  • You have previously received any cell therapy or gene therapy treatment.
  • You have taken part in another clinical trial or received experimental medication within the past month.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 2
Sponsor
Minovia Therapeutics Ltd.
Registry
clinicaltrials_gov
Start date
13 February 2019
Est. completion
9 March 2021

Where this trial is recruiting

🇮🇱 Israel

Primary endpoints

Number of participants with Treatment-related adverse events as assessed by CTCAE v5.0 following MNV-BM-BLD during a follow up period of 12 months post treatment.; IPMDS (International Pediatric Mitochondrial Disease Scale)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov